Dianthus TherapeuticsSTU:87E 22 PS Ratio is 3,037.04 as of Jul. 05, 2026, which is 2503% above its 10-year median of 116.67. GuruFocus rates STU:87E with a GF Score™ of 22/100 and a GF Value™ of €2.53 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 931 Biotechnology companies, Dianthus Therapeutics ranks worse than 98.28% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Dianthus Therapeutics's share price is €82.00.
Dianthus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03. Hence, Dianthus Therapeutics's PS Ratio for today is 3,037.04.
Warning Sign:
Dianthus Therapeutics Inc stock PS Ratio (=3043.23) is close to 3-year high of 3075.81.
The historical rank and industry rank for Dianthus Therapeutics's PS Ratio or its related term are showing as below:
STU:87E'
s PS Ratio Range Over the Past 10 Years
Min: 17.55 Med: 116.67 Max: 3075.81
Current: 3043.23
During the past 5 years, Dianthus Therapeutics's highest PS Ratio was 3075.81. The lowest was 17.55. And the median was 116.67.
STU:87E's PS Ratio is ranked worse than 98.28% of 931
companies
in the Biotechnology industry
Industry Median: 9.93
vs STU:87E: 3043.23
During the past 5 years, Dianthus Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 23.20% per year. The lowest was -50.30% per year. And the median was -13.55% per year.
Back to Basics: PS Ratio
Dianthus Therapeutics (STU:87E) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Dianthus Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dianthus Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Dianthus Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Dianthus Therapeutics's Share Price of today is €82.00. Dianthus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Dianthus Therapeutics (STU:87E) has a PS Ratio of 3,037.04 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Dianthus Therapeutics and its competitors. This is 2503% above median its historical median of 116.67. Over the past decade, Dianthus Therapeutics' PS Ratio has ranged from 17.55 to 3,075.81. According to the industry distribution chart, Dianthus Therapeutics ranks #915 out of 931 companies in the Biotechnology industry, placing it in the top 98.3%.
Is Dianthus Therapeutics' PS Ratio too high?
Dianthus Therapeutics' current PS Ratio of 3,037.04 is 2503% above median its 10-year median of 116.67. Over the past 10 years, this metric has ranged from a low of 17.55 to a high of 3,075.81. The Biotechnology industry median PS Ratio is 9.93. Dianthus Therapeutics' value of 3,037.04 is 30484.5% above this industry median. Based on the distribution chart, Dianthus Therapeutics ranks #915 out of 931 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Dianthus Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dianthus Therapeutics' PS Ratio compare to CAI and TNGX?
According to the Biotechnology industry distribution chart, Dianthus Therapeutics ranks #915 out of 931 companies for PS Ratio. This places Dianthus Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.93. Dianthus Therapeutics' value of 3,037.04 is 30484.5% above this benchmark. Historically, Dianthus Therapeutics' own PS Ratio has ranged from 17.55 to 3,075.81 over the past decade. While the company's 10-year median is 116.67 vs. the industry median of 9.93, Dianthus Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.93, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dianthus Therapeutics's current PS Ratio of 3,037.04 is 30484.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Dianthus Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dianthus Therapeutics's current PS Ratio is 3,037.04, which is 2503% above median its own 10-year median of 116.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dianthus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Dianthus Therapeutics (STU:87E) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.53, compared to a current price of €82.00 — trading 3141.1% above its estimated fair value. The current PS Ratio is 3,037.04, which is 2503% above median its 10-year median of 116.67 and 30484.5% above the Biotechnology industry median of 9.93. Dianthus Therapeutics' overall GF Score™ is 22/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Dianthus Therapeutics (STU:87E), the current PS Ratio is 3,037.04 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dianthus Therapeutics (STU:87E) Overvalued in 2026?
Based on GuruFocus' analysis, Dianthus Therapeutics stock appears to be overvalued.
The current stock price of €82.00 is trading 3141.1% above its estimated GF Value™ of €2.53.
GuruFocus considers Dianthus Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:87E:
PS Ratio: 3,037.04 (2503% above median its 10-year median of 116.67)
GF Value™: €2.53 vs. price of €82.00 (3141.1% above fair value)
Industry Position: 30484.5% above the Biotechnology median (#915 of 931)
No single metric tells the full story. See the STU:87E stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
22GF Score
Get the complete analysis for STU:87E
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:87E has been successfully added to your 
